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Abstract
Objective: Primary aims of the proposed protocol are to determine the feasibility/acceptability of the active
music engagement intervention protocol during hematopoietic stem cell transplantation (HSCT) and clinical
feasibility/acceptability of the biological sample collection schedule.
Design: The authors propose a single-case, alternating treatment design to compare levels of child and
caregiver cortisol in blood and saliva collected on alternating days, when the dyad receives and does not receive
AME sessions. Included are the scientific rationale for this design and detailed intervention and sample col-
lection schedules based on transplant type.
Setting/Location: Pediatric inpatient HSCT unit.
Subjects: Eligible participants are dyads of children 3–8 years old, hospitalized for HSCT, and their care-
giver. Children with malignant and nonmalignant conditions will be eligible, regardless of transplant type.
Intervention: AME intervention is delivered by a board-certified music therapist who tailors music-based
play experiences to encourage active engagement in, and independent use of, music play to manage the inter-
related emotional distress experienced by children and their caregivers during HSCT. Dyads will receive two
45-min AME sessions each week during hospitalization.
Outcome Measures: Eight collections of blood (child) and saliva (child/caregiver) will be performed for cortisol
measurement. The authors will also collect self-report and caregiver proxy measures for dyad emotional distress,
quality of life, and family function. At study conclusion, qualitative caregiver interviews will be conducted.
Results: Planned analyses will be descriptive and evaluate the feasibility of participant recruitment, cortisol
collection, planned evaluations, and AME delivery. Analysis of qualitative interviews will be used to gain an
understanding about the ease/burden of biological sample collection and any perceived benefit of AME.
Conclusions: Behavioral intervention studies examining biological mechanisms of action in pediatric
transplant populations are rare. Findings will provide important information about the feasibility/acceptability
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of collecting cortisol samples during a high-intensity treatment and advance understanding about the use of
active music interventions to mitigate child/caregiver distress during the transplant period.
Keywords: biomarker, cortisol, stress, music therapy, pediatric, hematopoietic stem cell transplant
Introduction
Hematopoietic stem cell transplantation (HSCT) is thecurative therapy of choice for many malignancies that
require high-dose chemotherapy, and sometimes radiation
therapy, and the only curative therapy option for some non-
malignant conditions such as hemoglobinopathies.1 Regard-
less of diagnosis, HSCT is an intense complex treatment with
many risks. Young children undergoing HSCT and their
caregivers are at particular risk for heightened emotional
distress, which is associated with physical symptom distress
and diminished quality of life and family function.2–9 In
addition, this acute emotional distress is related to traumatic
stress symptoms after treatment ends.8,10–15 Despite evidence
that young child and caregiver distress is inter-related, few
interventions have been developed to address this shared
distress3,8,9,13,16,17 and fewer specific to transplants.18
The active music engagement intervention uses music play
experiences to diminish stressful qualities of the treatment
environment, encouraging engagement and the use of posi-
tive coping strategies to reduce the emotional/traumatic dis-
tress experienced by young children (ages 3–8 years) and
caregivers and improve quality of life.19–21 Early studies
established AME as beneficial in managing child emotional
distress19–21 and explored caregiver benefit.21 The aim of the
current R01 mechanistic trial (NR015789) is to identify be-
havioral, sociological, and psychological variables that con-
tribute to positive health outcomes observed in early AME
studies. To date, the authors’ studies have focused on short
inpatient admissions for chemotherapy and identification of
psychosocial mechanisms of action. In this study, the authors
will explore the feasibility/acceptability of AME during the
acute phase of HSCT, which is a high-intensity treatment
requiring 3–6 weeks of hospitalization. In addition, to expand
the understanding about how active music interventions work
to mitigate transplant-related stress, the authors will also
explore the feasibility/acceptability of collecting the stress
biomarker, cortisol, from children and caregivers.
Evidence that increased hypothalamic–pituitary–adrenal
(HPA) axis activity stimulates the release and production of
inflammatory biomarkers, which in turn is associated with
negative health outcomes for individuals undergoing treat-
ment for chronic conditions and caregivers, supports inves-
tigation of biological pathways underlying the use of active
music to mitigate transplant-related stress.22–24 Cortisol is a
steroid hormone secreted by the HPA axis in response to
acute and prolonged stress, and assaying various bodily fluids
for cortisol is a widely used method of indexing HPA axis
activity in children.25 To date, few intervention studies have
looked at cortisol in pediatric patients with malignant and
nonmalignant conditions,26–28 and of those, only one used
music28 and none involved children and caregivers.26–28 This
is likely due to challenges associated with cortisol collection
and interpretation during cancer and HSCT treatment and
difficulties conducting fully powered, randomized interven-
tion trials in low-incidence populations.29–31 To overcome
these challenges, the authors propose a single-case design
study, which allows for estimation of intervention effects in
small samples drawn from low-incidence populations.
The authors’ primary aims are to determine the feasibili-
ty/acceptability of the AME intervention protocol during
HSCT and evaluate clinical feasibility/acceptability of the
schedule for biological samples required when using a single-
case design. If the authors meet feasibility thresholds for blood
and salivary cortisol (collection and sample quantity/quality),
they will examine changes in parent and child cortisol levels
relative to the AME intervention. The secondary aim is to
examine the feasibility of completing self-report measures
used in prior AME studies in the context of HSCT. This
secondary aim will also establish whether it is feasible/ac-
ceptable to collect both biological and self-report data during a
high-intensity treatment in subsequent trials. Areas of evalu-
ation include activities/timelines related to recruitment, blood
and salivary cortisol collection, planned evaluations, and in-
tervention delivery. Specific research questions are as follows:
(1) What percentage of eligible child/caregiver dyads
consent to study participation?
(2) What percentage of AME sessions do child/caregiver
dyads complete?
(3) What percentage of planned measures [other than
cortisol] do caregivers complete?
(4) What percentage of planned cortisol samples are
collected and what percentage of these samples yield
usable data?
(5) What are caregivers’ perspectives about the relative
ease/burden of biological sample collection, benefit
(or nonbenefit) of AME for managing distress, and
enhancing family and quality of life outcomes for self
and child?
Materials and Methods
Conceptual framework
The conceptual framework (Fig. 1) is based on Robb’s
Contextual Support Model of Music Therapy19,32,33 and
further informed by Kazak’s Pediatric Medical Traumatic
Stress Model, which provides a useful heuristic for under-
standing short- and long-term consequences of HSCT
treatment for children and caregivers.4 In this framework,
recurring events related to HSCT (i.e., hospitalization,
symptom distress, and procedures) are viewed as potentially
traumatic events. Caregiver appraisal of events as traumatic
or not traumatic is influenced by pre-existing factors, which
serve as antecedents. Research indicates that higher child
and caregiver distress during HSCT is related to (1) demo-
graphics (younger child/caregiver age, female caregiver
gender, and lower socioeconomic status/education),34,35
(2) higher caregiver/child distress with prior hospitaliza-
tions and greater traumatic stress symptoms,2,36,37 and (3)
disease and treatment characteristics (diagnosis and trans-
plant type).5,12,14,15,38
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The AME is designed to directly target potential proximal
mediators of child engagement and caregiver–child inter-
action,19,21 as well as distal mediators of perceived family
normalcy,39 caregiver confidence (self-efficacy) about their
ability to support their child during treatment,40 and inde-
pendent music play between therapist-led sessions. Out-
comes include child outcomes (emotional distress, physical
symptom distress, cortisol, and quality of life), caregiver
outcomes (emotional distress, traumatic stress symptoms,
cortisol, and quality of life), and family function.
Study design and rationale
In this one-group pilot study (Fig. 2), approved by the
Indiana University Institutional Review Board, children and
their caregivers will receive two 45-min AME sessions each
week during the acute phase of HSCT until time of dis-
charge (i.e., two sessions/week for duration of treatment).
Session frequency and duration were selected based on
preliminary studies and HSCT symptom trajectory.19–21,41
The total number of sessions will be based on the individual
child’s admission period to account for variations in treat-
ment duration, to mimic standard care, and to avoid removal
of AME as a supportive care service before discharge when
children and caregivers still require support. The authors
anticipate that a majority of patients will receive six ses-
sions, over a 3-week period, and to collect data on the
number of sessions each dyad receives to inform analysis
and interpretation of findings.
Single-case designs were developed to facilitate exami-
nation of treatment when data can only be collected from a
small number of individuals, such as when investigating
different approaches to behavior modification among indi-
viduals with rare developmental disabilities.42 Using the
single-case alternating treatment design, the authors com-
pare levels of cortisol in blood and saliva samples collected
from dyads on days when they receive AME sessions with
levels of cortisol on days when they do not receive AME.
Since relatively few children receive HSCT, the single-case
design is ideal for evaluating interventions during trans-
plants.43 The essential logic of the single-case design, as
implemented in this study, is that levels of cortisol will be
consistently and clearly lower on days when dyads receive
AME than on days when they do not. If the analyses, as
described below, reveal that this is the case, the authors may
infer that AME caused observed reductions in cortisol.44
Participants and recruitment
Children/caregivers will be study eligible if the child (1)
is 3–8 years of age (inclusive) at the time of enrollment; (2)
will receive inpatient HSCT for a malignant or nonmalig-
nant condition, including hemoglobinopathies; and (3) has
one caregiver who agrees to be present for all sessions.
Children/caregivers will not be eligible if (1) the caregiver or
child does not speak English or (2) if the child has a sig-
nificant cognitive impairment that may hinder their ability
to participate, as determined by consultation with the at-
tending HSCT physician, primary hematologist–oncologist,
and caregivers. Eligibility will not be dependent on trans-
plant type (autologous or allogeneic).
The authors will enroll children, ages 3–8 years, admitted
for HSCT and one caregiver (i.e., parent or legal guardian)
FIG. 1. Conceptual framework. AME, active music engagement; ESAS, Edmonton Symptom Assessment System;
PCL-S, PTSD checklist; PIES, Prior Illness Experiences Scale.
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as dyads. The targeted sample size is four child–caregiver
dyads, which will provide the information needed to de-
termine the feasibility/acceptability of study procedures and
refine intervention content. Certified research coordinators
will use an eligibility checklist to identify potential partic-
ipants, and a study team member will provide study infor-
mation, verify eligibility, and obtain written caregiver
consent/assent for children ‡7 years.
Active music engagement intervention
Dyads will receive two 45-min AME sessions in private
rooms at the HSCT unit each week for the duration of their
inpatient stay. AME sessions were designed for delivery by a
board-certified music therapist (MT-BC) who tailors music-
based play experiences to encourage active engagement in
and independent use of music play as a strategy to manage
distress.19–21 During sessions, the MT-BC provides dyads
repeated opportunities to experience competence, autonomy,
and meaningful interactions through music-based play activ-
ities and provides support/education about ways that chil-
dren/caregivers can use music play to manage distress and
sustain a sense of family normalcy while being hospitalized
and following HSCT discharge. AME has three primary
components: (1) therapist-led music-based play activities and
sessions, (2) a music play resource kit (to promote indepen-
dent music play), and (3) session planning and caregiver tip
sheets that focus on ways to use music play during hospital-
ization and as dyads transition from hospital to home
(Table 1).
Biological sample collection
The authors developed two sampling schedules based on
transplant type (Figs. 3 and 4) to address differences in
conditioning treatment protocols for autologous and allo-
geneic transplants and to avoid periods of treatment with
corticosteroids, which can interfere with cortisol measure-
ments. Biological samples collected will include blood
(child) and saliva (child and caregiver). Blood (1 mL) will
be collected from the child’s central line as part of daily
transplant laboratories (drawn 4–6 am). The blood, in rapid
serum tubes, will be sent immediately to the pathology
laboratory for cortisol analysis using a Beckman Coulter
UniCel DxI800 immunoassay system. Saliva will be col-
lected from the child and caregiver by study staff at three
different time points on each collection day: (1) up to 1 h
before the AME session, (2) up to 1 h after the session, and
(3) 1–3 h after the second collection. To collect saliva, the
child and caregiver will be instructed to drool into 50-mL
conical tubes until *500 mL of saliva is collected. The sa-
liva will be immediately stored on dry ice and transferred to
-80C until analysis. Salivary cortisol levels will be mea-
sured using an R&D Systems cortisol parameter assay. For
child participants, the authors will capture medical record
data on any medications that can affect cortisol levels. In
addition, caregivers will complete a questionnaire (for self
and child) about activities or substances known to affect
cortisol levels (e.g., sleep, exercise, and caregiver medica-
tions) and timings/details of food intake.45
For this single-case design, the authors will also collect
biological measures on treatment and nontreatment days,
controlling for time of day (to account for daily fluctuations
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in cortisol) and potential order effects. As seen in Figure 3,
the sampling schedule for autologous transplants includes
eight collections (4 treatment days and 4 control days).
The first four collections occur during conditioning for the
transplant; and the remaining four occur poststem cell
infusion. Note that the first collection serves as the
baseline for autologous participants. Treatment and control
days are linked (they occur 1 day apart and take place at the
same time of day), with four linked collections scheduled
over the course of the transplant.
The sampling schedule for allogeneic transplants (Fig. 4)
is similar; however, the timing of collection is adjusted to
account for drug interference that occurs during condition-
ing. Because allogeneic collections occur later in treatment,
the authors will collect baseline blood samples during a
routine clinic visit 1 week before admission. In addition,
before side effects (e.g., mucositis) occur, the authors will
schedule two practice collections to help children learn how
to give saliva samples. In both transplant regimens, the
number of collections exceeds the recommended number of
three data points per condition established for single-case
designs.46
Caregiver report measures
Caregivers will complete self-report and caregiver proxy
questionnaires at four time points (Table 2). Baseline mea-
sures will be completed during a routine clinic visit, within
30 days of the child’s scheduled HSCT admission. Time 2
measures will be completed post-AME session eight, Time 3
measures at the time of discharge (if discharge did not occur
at time of session eight), and Time 4 measures at 100 days
post-transplant during a subsequent clinic visit. In addition,
caregivers will complete brief pre/postsession measures for
caregiver distress/child symptom distress at sessions 2, 4,
and 6. All measures will be administered by trained evalu-
ators not involved with AME delivery, and all evaluation
sessions audio-recorded for quality assurance monitoring.
The authors selected questionnaires based on the study’s
theoretical framework (Fig. 1), with careful consideration of
psychometric properties, sensitivity to change, and response
burden. Table 2 provides a list of all measures, including
psychometrics and administration schedule.47–53
Caregiver qualitative interviews
The authors will conduct semistructured qualitative inter-
views with caregivers to identify any changes that may be
required for AME delivery during HSCT and evaluate ac-
ceptability of study activities/timelines related to biological
sample collection, planned evaluations, and intervention de-
livery. Interviews will begin with an open-ended question to
capture overall perceptions of the caregiver’s experience (i.e.,
‘‘Please tell me about your experience of participating in the
Table 1. Active Music Engagement Intervention Components and Theoretical Principles
Intervention component Theoretical principles
Component 1: Music-Based
Play Activities
(1) Predictable environment provides a structure that supports child competence.
Therapist uses familiar music activities to provide structure and increase child’s ability to
predict what will happen in their environment.
(2) Leveled activities help ensure success and support child competence.
Therapist tailors physical activity requirements to meet the individual needs of each child.
Enables child success and engagement during periods of high or fluctuating symptom
distress.
(3) Opportunities to make independent decisions support child autonomy.
Children choose from a variety of music play activities, and each activity includes a wide
range of materials. Activities include a wide range of materials and activity options so
that the child can make choices for self and others.
Therapist uses improvisational techniques to follow child-initiated changes in their music
making (e.g., child changes tempo or style of playing).
(4) Activities structured to support caregiver–child interaction.
Activities structure and support reciprocal caregiver–child interactions. The therapist
individualizes experiences to support increased frequency and quality of interactions.
Component 2: Music Play
Resource Kit
Supports independent use of music play to manage distress between therapist-led
sessions.
Activities mirror content from therapist-led sessions. The kit includes:
(1) Professional CD recording of music composed and/or arranged specifically for the
AME intervention.
(2) Age-appropriate musical instrument and play materials that correspond to each
activity.
(3) Activity cards designed to give children/caregivers at-a-glance information on ways
they can use their kit.
Component 3: Session Planning
and Caregiver Tip Sheets
(1) Promotes caregiver competence about how children use play to cope and ways to
engage their child in music play during the transplant period.
(2) Promotes caregiver autonomy by empowering caregivers with skills/resources to
support their child during treatment.
(3) Supports caregiver–child relationships through normalizing music-based play
activities.
AME, active music engagement.
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FIG. 3. Autologous transplant
biological sample collection
timetable.
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FIG. 4. Allogeneic transplant bio-
logical sample collection timetable.
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music play sessions with your child.’’). Follow-up questions
will include specific questions about the perceived benefit
(or nonbenefit) of AME in managing stress, experiences with
saliva collection, and the value of different intervention
components (i.e., tip sheets, goal setting worksheet, and kit
use). Interviews will occur within 2 weeks of Time 2 data
collection (in the hospital or by phone). Trained personnel, not
involved in AME delivery, will conduct audio-recorded in-
terviews for subsequent transcription and analysis.
Data analysis plan
The following analysis includes a systematic plan to ad-
dress primary and secondary aims of the proposed pilot
Table 2. Measures
Variable(s) Measure
No. of
items
Reliability
evidence Admin. schedule Completed by
Antecedent factors
Demographics Family Information Form 3 N/A T1 Parent
Parent/child age, parent
gender, SES, parent
education
Prior distress
w/hospitalization
Prior Illness Experiences
Scale
13 0.78a T1 Parent
Parent/child Abbreviated PTSD
Checklist (PCL-S)
6 0.94a T1, T2, T3, T4 Parent
Disease characteristics Diagnosis and Treatment
Form
2 N/A T4 Research
Assistant (RA)
Treatment characteristics Medication Data Form N/A N/A T1, T2, T3, T4 RA
Proximal mediators
Child engagement Behavioral Coding Form N/A 0.85b Sessions 2, 4, 6 Trained Coder
Parent–child interaction Behavioral Coding Form N/A 85b Sessions 2, 4, 6 Trained Coder
Distal mediators
Family normalcy
perspective
Family Management
Measure
14 0.90a T1, T2, T3, T4 Parent
Family Life Difficulty
Subscale
Parent self-efficacy Parental Beliefs Scale 20 0.85a T1, T2, T3, T4 Parent
Independent music play Parent Report 2 N/A Sessions 2–6; T4 Parent
Child outcomes
Child emotional distress CHQ—Mental Health
Subscale
16 0.81a T1, T2, T3, T4 Parent
Child physical symptom
distress
(mood, anxiety, pain,
fatigue, nausea)
Edmonton Symptom
Assessment System
5 0.69–0.80a T1, T4
Sessions 2, 4, 6
Parent
Child quality of life KINDLR 20 0.89a T1, T2, T3, T4 Parent
Neurophysiological
indicator of stress
Cortisol (serum; salivary) N/A N/A Appendix 5, 6 Nurse (serum);
RA (salivary)
Parent outcomes
Parent emotional and
traumatic stress
symptoms
Profile of Mood States-Short
Form
37 0.99c T1, T2, T3, T4 Parent
Impact of Events Scale-
Revised (IES-R)
22 0.84–0.91a T1, T2, T3, T4 Parent
Parent distress (mood,
anxiety, fatigue)
Edmonton Symptom
Assessment System
3 0.69–0.80a T1, T4
Sessions 2, 4, 6
Parent
Parent quality of life Index of Well-being 9 0.93a T1, T2, T3, T4 Parent
Neurophysiological
indicator of stress
Cortisol (salivary) N/A N/A Appendix 6 RA
Parent/child outcomes
Family function FACES II 30 0.90a T1, T2, T3, T4 Parent
Qualitative interviews
Parent acceptability Parent Interview N/A N/A T4 Parent
aCronbach’s a.
bInter-rater reliability.
cCorrelation with POMS.
FACES, Family Adaptability and Cohesion Evaluation Scale; POMS, Profile of Mood States.
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study. Descriptive statistics will be computed for all vari-
ables to ensure data quality.
Research questions 1–3. Analyses will be descriptive.
The authors will report the percentage of (1) eligible care-
giver/child dyads who consent to study participation (fea-
sibility threshold = 75%) and reasons that eligible dyads
decline study participation, (2) planned intervention activi-
ties that dyads complete (acceptability threshold = 75%) and
reasons for canceled, rescheduled, and missed sessions, and
(3) planned measures that caregivers complete at Time 1,
Time 2, Time 3, and Time 4 data collections (feasibility
threshold = 75%), including examination of missing data
patterns.
Research question 4. Analyses will be descriptive. In
the first portion of these analyses, the authors will report the
percentage of cortisol samples collected from children
(feasibility threshold = 75%) and caregivers (feasibility
threshold = 85%). In the second portion, the authors will
report the proportion of samples judged to be of sufficient
quality for further analyses, such that cortisol values fall
within the range for which the assay has been validated as
well as the distribution of values collected from other
children and caregivers across the study. Given the poten-
tial for children’s samples to be altered by ingestion of food,
drink, or medication, the authors will establish a lower
feasibility threshold for children (60%) than for their
caregivers (75%).
Research question 5. The authors will use a qualitative
descriptive design with content analysis to analyze interview
data.54 Procedures include (1) interviews transcribed and
reviewed for accuracy; (2) category development through
content analysis; and (3) findings validated by peer review
to reach consensus.
Biomarker analysis plan
Assuming that the feasibility thresholds specified above are
met, blood and salivary cortisol levels will be graphed to
visualize trends.55 To complement the results of these visual
analyses, the authors will compute Tau-U statistics. The Tau-
U statistic is a nonoverlap metric derived by comparing all
unique pairs of data points (here, cortisol levels) between the
treatment and control conditions. Before analysis, data will be
inspected for linear trends indicative of serial conditioning
effects. These effects may occur when cortisol levels mea-
sured at points in the intervention are subject to the current
and prior effects of the intervention. If conditioning effects
are detected, the calculation of the Tau-U statistic will be
adjusted for linear trends using utilities embedded in the Tau-
U calculator. The Tau-U statistics will then be used to esti-
mate an effect size for the treatment on levels of cortisol for
each participant and for the sample as whole.56
Discussion
Importance
Pediatric HSCT has proven to be an effective treatment
for many pediatric malignancies as well as certain non-
malignant hematologic conditions. Advances in condi-
tioning regimens and donor options have also expanded to
populations for whom HSCT can be beneficial, including
metabolic disorders, immunodeficiencies, and even in-
flammatory bowel disease.57 While it is encouraging that
HSCT is a therapeutic option for increasing numbers of
otherwise incurable diseases, HSCT also raises concern
that more children and caregivers will endure significant
stress associated with the transplant and will need greater
availability and variety of supportive care options.58 AME,
as described in this protocol, not only provides support to
the child and caregiver during the acute period of HSCT
but also builds coping skills after HSCT when psychosocial
concerns such as traumatic stress symptoms emerge.59,60
Because HSCT is a complex treatment, an important aspect
of this study is to ensure that AME and study-related ac-
tivities do not interfere with planned treatment protocols,
thereby avoiding creation of undo stress for the treatment
team and child–caregiver dyads. As such, this study rep-
resents an important step for refining AME for delivery
during HSCT and advancing the understanding about the
use of active music interventions to manage acute stress for
this growing patient population.
Method strength
Conventional research designs (e.g., randomized control
trials) require relatively large samples to assess treatment
effects; however, as previously noted, single-case designs
were developed for use in contexts where data can be col-
lected from only a small number of individuals. Applying a
single-case design to the study of HSCT will allow esti-
mation of the effects of AME on an understudied population
of children. Moreover, by collecting cortisol levels at mul-
tiple time points, it will be possible to isolate AME effects
on different aspects of HPA axis activity (i.e., waking cor-
tisol levels, baseline levels, or diurnal cortisol throughout
the day) by comparing levels of cortisol that correspond to
different aspects of HPA axis activity on treatment and
control days. Additionally, hospitalization will provide a
controlled environment where medical records can be used
to identify events that may contribute to unexpected fluc-
tuations in cortisol levels, allowing for more accurate data
interpretation.
Potential limitations
For children with malignant disease requiring HSCT,
there may be long-term effects of therapy on the HPA
axis.29,61–63 This may create difficulties in interpretation of
patient cortisol levels and the potential clinical benefit of
AME. Collection of baseline cortisol may be useful in dif-
ferentiating between long-term treatment effects and the
effects of AME. Additionally, HSCT-related side effects,
such as pain associated with mucositis or general malaise,
might result in patients choosing not to provide a biological
sample. Finally, the inability of consenting caregivers to be
present for all AME sessions and saliva collections due to
work or other caregiver responsibilities may result in missed
collections.
This study will provide important information about the
feasibility/acceptability of collecting cortisol samples at the
frequency required for single-case design from young
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children and caregivers during a high-risk high-intensity
treatment. In addition, findings will advance the under-
standing about the use of active music interventions to
mitigate the inter-related distress experienced by children
and caregivers during the transplant period.
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